But theyre not meant to be a long-term solution when FDA-approved options are available
At Pure Med Spa , we are dedicated to providing a supportive, medically-sound environment for your weight loss journey
Meanwhile, semaglutide 2.4 mg daily (Wegovy, Novo Nordisk) resulted in weight loss of up to 13.9% (95% CI, 11%-16.7%) after 68 weeks of therapy, whereas liraglutide at 3 mg daily (Saxenda, Novo Nordisk) reduced weight by up to 5.8% (95% CI, 3.6%-8%) after 26 weeks
The surge in demand has led to supply shortages, making it harder for diabetic patientsthose for whom the drugs were originally developedto get their prescriptions filled
Still, numbers alone do not tell the whole story
However, there is still a significant difference between the WL that can be achieved with bariatric surgery and the currently approved obesity pharmacotherapies and there is heterogeneity in treatment responses with GLP-1 RA (for example people with T2D may achieve less WL compared to those without diabetes in clinical trials, despite similar lifestyle interventions) [13, 14]
/assets/images/provider/photos/2802570.png)
